Skip to main content

Circulating Tumor Cells TheRapeutic APheresis: a novel biotechnology enabling personalized therapy for all cancer patients

Objective

"Chemotherapy is slowly being supplemented by a new generation of drugs that recognize specific targets in or on cancer cells and has proven to be more effective with markedly fewer side effects. During the course of the disease alternative oncogenic signaling pathways take over inevitably leading to drug resistance. As a consequence renewed tumor analysis is required to redefine the optimal treatment regiment. However a biopsy can frequently not be obtained without risk and or discomfort to the patient. Circulating tumor cells (CTC) may circumvent this problem.
CTC refer to cells that detach from a primary tumor or metastatic site, circulate in the peripheral blood and may form metastasis. CTC represent a ""liquid biopsy"" that can be used to tailor treatment for individual patients. CTC are however rare and can only be obtained for further characterization in a small fraction of patients.
In the CTCtrap consortium universities, research institutions and SMEs are linked in a common effort, starting from the simple, but innovative view of using Therapeutic Apheresis (TA), as a way to collect CTC from peripheral blood in cancer patients.
A new TA column will be developed to capture CTC and then reintroduce the blood devoid of tumor cells back into the body with the promise to obtain CTC in all patients at risk for recurrence or diagnosed with metastatic disease. The molecular characterization of these CTC is expected to gather new knowledge on metastasis' mechanism, provide a risk assessment and the optimal therapy choice during the course of the disease of cancer patients. The new knowledge on CTC heterogeneity within cancer type and within individuals will allow for the tuning of CTCapheresis to specific cancer types. Prospective pilot studies will be setup to investigate the feasibility of the CTCapheresis in the clinic and their potential therapeutic benefit.
Success of CTCapheresis will lead to a radical change in the diagnosis and treatment of solid tumors."

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Coordinator

UNIVERSITEIT TWENTE
Address
Drienerlolaan 5
7522 NB Enschede
Netherlands

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ferdinand Damhuis (Mr.)
EU contribution
€ 970 000

Participants (11)

INSTITUT GUSTAVE ROUSSY
France
EU contribution
€ 386 250
Address
Rue Camille Desmoulins 39
94805 Villejuif

See on map

Activity type
Research Organisations
Administrative Contact
Arnauld Forest (Mr.)
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
United Kingdom
EU contribution
€ 636 250
Address
Old Brompton Road 123
SW7 3RP London

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Lydia Turner (Ms.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN

Participation ended

Germany
Address
Geschwister-scholl-platz
72074 Tuebingen

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tanja Fehm (Prof.)
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany
EU contribution
€ 386 250
Address
Geschwister Scholl Platz 1
80539 Muenchen

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Brigitte Rack (Dr.)
SZEGEDI BIOLOGIAI KUTATOKOZPONT
Hungary
EU contribution
€ 383 750
Address
Temesvari Korut 62
6726 Szeged

See on map

Activity type
Research Organisations
Administrative Contact
Csaba Vizler (Dr.)
Participant Legal name Istituto Oncologico Veneto IRCCS
Italy
EU contribution
€ 636 250
Address
Via Gattamelata
35128 Padova

See on map

Activity type
Research Organisations
Administrative Contact
Rita Zamarchi (Dr.)
LEUKOCARE AG
Germany
EU contribution
€ 810 000
Address
Am Klopferspitz
82152 Martinsried/munich

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Martin Scholz (Prof.)
ASPER BIOTECH AS
Estonia
EU contribution
€ 610 000
Address
Vaksali 17a
50410 Tartu

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Anu Aaspõllu (Dr.)
ACZON SRL
Italy
EU contribution
€ 185 000
Address
Via Lavino 265 D
40050 Monte San Pietro Bo

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Alfredo Ventola (Dr.)
AQUAMARIJN MICRO FILTRATION BV
Netherlands
EU contribution
€ 610 000
Address
Singel 58 B
1015 AB Amsterdam

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Arjan Tibbe (Dr.)
HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
Germany
EU contribution
€ 386 250
Address
Universitaetsstrasse 1
40225 Dusseldorf

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Doris Neubert